

Claims

1. A pharmaceutical formulation for oral administration with extended
release properties comprising an amount of gepirone hydrochloride, an
5 amount of a cellulosic polymer matrix and an amount of
microcrystalline cellulose characterised in that the amount the
pharmaceutically acceptable cellulosic polymer matrix is from 70 to 85
wt %, the amount of carbohydrate binder is from 7 to 10 wt % and the
amount of gepirone hydrochloride is from 13 to 21 wt %.
- 10 2. The pharmaceutical formulation according to claim 1, characterised in
that the cellulosic polymer matrix is a hydroxymethyl propylcellulose
having a viscosity of 15,000 cps to 100,000 cps.
- 15 3. The pharmaceutical formulation according to claim 1, characterised in
that the microcrystalline cellulose is Avicel pH 101.
4. A treatment for depression or a related central nervous system disorder
with gepirone administered in a once-a-day oral formulation for
20 extended release of gepirone, characterised in that the formulation is
according to claim 1.